Filing Flows › Lineage Cell Therapeutics (LCTX) › How it makes money
How Lineage Cell Therapeutics (LCTX) makes money
Lineage Cell Therapeutics (LCTX) made $1.1M of revenue in the second quarter 2026 (Q2 2026), +359% from a year earlier. Collaboration Revenues brought in $943K (88%); Royalties License and Other Revenues brought in $126K (12%).
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Collaboration Revenues | $943K | 88.2% | -40% | — |
| ↳ Upfront License Fees | $600K | 56.1% | -30% | -76% |
| ↳ Event Based Milestones and Other Collaborative Revenue | $343K | 32.1% | -52% | — |
| Royalties License and Other Revenues | $126K | 11.8% | -16% | -46% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $1.1M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $1.1M | -61% |
| Q1 2026 | $1.7M | +15% |
| Q4 2025 | $6.6M | +130% |
| Q3 2025 | $3.7M | -3% |
| Q2 2025 | $2.8M | +96% |
| Q1 2025 | $1.5M | +4% |
| Q4 2024 | $2.9M | +37% |
From Lineage Cell Therapeutics' 10-Q filed Aug 6, 2026 (on EDGAR).
Questions
How does Lineage Cell Therapeutics make money?
Lineage Cell Therapeutics (LCTX) made $1.1M of revenue in the second quarter 2026 (Q2 2026), +359% from a year earlier. Collaboration Revenues brought in $943K (88%); Royalties License and Other Revenues brought in $126K (12%).
What is Lineage Cell Therapeutics' biggest business?
Collaboration Revenues: $943K in the second quarter 2026, 88% of revenue.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.